Trial Profile
An 8-week, Double-Blind, Randomized, Multicenter, Flexible-Dose, Placebo-Controlled Pilot Study of Pagoclone in Patients With Persistent Developmental Stuttering Followed by a 52-week Open-Label Extension.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Jun 2014
Price :
$35
*
At a glance
- Drugs Pagoclone (Primary)
- Indications Stuttering
- Focus Therapeutic Use
- 09 Jun 2014 New trial record